Published in Drug Week, April 8th, 2005
"Aphidicolin, a tetracyclic diterpene antibiotic produced by Cephalosporium aphidicola, is under investigation as anti-cancer drug," oncologists in Germany explained. "Because of its poor solubility in water, it cannot be administered directly in vivo."
"Systemic application of aphidicolin glycinate or aphidicolin gamma-cyclodextrin complexes resulted in tumor growth inhibition but not in cures," noted M. Michaelis and colleagues at J.W. Goethe University Hospital. "To improve the pharmacokinetics, a liposomal preparation of aphidicolin was developed and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.